The present invention discloses a system and method for increasing the lifespan and quality of life of human beings and other mammals. This discloses methods for preparing and delivering various health and longevity compositions. The compositions of the present invention are selected and designed for the purpose of efficiently delivering health and longevity enhancing therapies through oral supplementation, misting, nasal spray, suppository, etc. An existing compound known to have capacity for life extending potential, rapamycin, is combined with a non-toxic therapeutic anabolic hormone, e.g., DHEA, and cannabidiol (CBD) to enable absorption and effect. These three compounds work together to dramatically improve both the quality of life in aging humans and other mammals as well as extending the life of humans potentially up to 120 healthy years. One preferred embodiment provides a method for continuous low dose supplementation, e.g., incorporated in or with a daily meal. This invention not only resolves the issue of anti-aging of higher life forms, without toxicity, but provides for an improved method for absorption.

The present invention relates to a method of manufacturing of an immediate release oral liquid formulation comprising ospemifene. Also relates to a self-emulsifying drug delivery system, a self-microemulsifying drug delivery system and a self-nanoemulsifying drug delivery system for oral administration comprising ospemifene and manufacturing methods thereof. Interestingly, the formulations presented in the invention avoid the need for food intake by the patient in need of such treatment previously required for increased bioavailability of Ospemifene tablet formulations.

The present invention relates to a method of manufacturing of an immediate release oral liquid formulation comprising ospemifene. Also relates to a self-emulsifying drug delivery system, a self-microemulsifying drug delivery system and a self-nanoemulsifying drug delivery system for oral administration comprising ospemifene and manufacturing methods thereof. Interestingly, the formulations presented in the invention avoid the need for food intake by the patient in need of such treatment previously required for increased bioavailability of Ospemifene tablet formulations.

The present invention provides nutraceutical composition comprising essential bioactives such as spice powders and their extracts in a vesicle made up of edible amphiphilic lipid as emulsifiers and surfactants for antioxidant, antiviral, antibacterial, antifungal and anti-inflammatory effects. Specifically, the nutraceutical composition of the present invention synergistically enhances intestinal absorption and helps in reducing inflammation and infections. The present invention also provides a method of producing the afore-mentioned nutraceutical composition.

The present invention provides nutraceutical composition comprising essential bioactives such as spice powders and their extracts in a vesicle made up of edible amphiphilic lipid as emulsifiers and surfactants for antioxidant, antiviral, antibacterial, antifungal and anti-inflammatory effects. Specifically, the nutraceutical composition of the present invention synergistically enhances intestinal absorption and helps in reducing inflammation and infections. The present invention also provides a method of producing the afore-mentioned nutraceutical composition.

A hybrid composition of partially pre-gelatinized cassava starch powder is herein disclosed. The hybrid composition is obtained by a pre-compaction process and a wet-granulation process, and the partially pre-gelatinized cassava starch including birefringent portions and non-birefringent portions. The hybrid composition is formulated for use in, for example, tablets, and may be used as a multi-functional excipient in various powder formulations.

A hybrid composition of partially pre-gelatinized cassava starch powder is herein disclosed. The hybrid composition is obtained by a pre-compaction process and a wet-granulation process, and the partially pre-gelatinized cassava starch including birefringent portions and non-birefringent portions. The hybrid composition is formulated for use in, for example, tablets, and may be used as a multi-functional excipient in various powder formulations.

A lubric gel composition for personal defense includes a fatty acid at a concentration ranging from 5 wt % to 10 wt % of the composition, a thickening agent at a concentration ranging from 1.75 wt % to 8.75 wt % of the composition, a detergent at a concentration ranging from 1.03 wt % to 4.07 wt % of the composition, a surfactant at a concentration ranging from 2 wt % to 15 wt % of the composition, and water at a concentration ranging from 66 wt % to 90.21 wt % of the composition.

A lubric gel composition for personal defense includes a fatty acid at a concentration ranging from 5 wt % to 10 wt % of the composition, a thickening agent at a concentration ranging from 1.75 wt % to 8.75 wt % of the composition, a detergent at a concentration ranging from 1.03 wt % to 4.07 wt % of the composition, a surfactant at a concentration ranging from 2 wt % to 15 wt % of the composition, and water at a concentration ranging from 66 wt % to 90.21 wt % of the composition.

The present invention relates to a stable crystal form, i.e. form A, of 2-tert-butyl-4-methoxyphenol, and to a new preparation method for the 2-tert-butyl-4-methoxyphenol; and the use of the 2-tert-butyl-4-methoxyphenol and the stable crystal form thereof, i.e. form A, in preparing antitumor drugs or immunomodulator drugs. The stable crystal form, i.e. form A, as expressed by a powder X-ray diffraction pattern in an angle of 2θ, using Cu-Kα radiation, has at least 3 absorption peaks selected from the following positions: 6.27±0.10, 6.94±0.10, 12.27±0.10, 13.36±0.10, 14.01±0.10, 14.79±0.10, 15.31±0.10, 17.05±0.10, 18.30±0.10, 19.00±0.10, 20.47±0.10, 20.98±0.10, 22.37±0.10, 23.68±0.10, 24.55±0.10, 25.37±0.10, 30.83±0.10, 33.12±0.10, 40.50±0.10, 42.81±0.10.